Overview
Embecta designs, manufactures, and distributes insulin delivery devices worldwide, including pen needles, insulin syringes, and safety injection devices, with about 8 billion units produced annually for patients in over 100 countries. It generates revenue from selling these products to wholesalers and distributors, and runs manufacturing facilities in the United States, Ireland, and China after spinning off from BD. The company briefly pursued a tubeless insulin patch pump but later refocused on core injection-delivery products, and in 2026 announced plans to acquire Owen Mumford to broaden its drug-delivery platforms. Its goal is to be a leading global supplier of insulin-delivery devices and to expand into related areas of drug delivery through selective acquisitions.
Work here?Claim your company
Simplify's take
What believers are saying
- Embecta closed Owen Mumford on May 15, 2026, expanding into obesity and autoimmune.
- Q3 fiscal 2026 raised adjusted operating margin to 23.5%-24.0% and EPS to $1.80-$1.90.
- Management targets about $150 million debt repayment in 2026 and $95 million-$105 million free cash flow.
What critics are saying
- U.S. revenue shortfall forced 2026 guidance cuts and a cost-structure review.
- Tariffs and local-buying sentiment threaten margins, suppliers, and regional sales momentum.
- Heavy debt and acquisition integration risk constrain flexibility if Owen Mumford underperforms.
What makes embecta unique
- Embecta pairs 1924 insulin-device heritage with Owen Mumford’s drug-delivery IP.
- Its global manufacturing and distribution network reaches more than 100 countries.
- Aidaptus adds a pharmaceutical auto-injector platform beyond diabetes injection consumables.
Help us improve and share your feedback! Did you find this helpful?